The challenge is that a group of people are going to profit massively from this ...

r00fus on June 11, 2021 | parent | context | favorite | on: Third member of U.S. FDA advisory panel resigns ov...

The challenge is that a group of people are going to profit massively from this drug being approved. Some patients are going to pay $56K+ on this treatment, in other cases, we taxpayers are going to pay that (Medicare/Medicaid).

Should this be approved if it's ineffective?